Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Mechanism  




2 See also  




3 References  













FGI-104






●العربية
 ●فارسی
 ●Français
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

FGI-104
Legal status
Legal status
Identifiers

  • 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-6-[4-(hydroxymethyl)-3-methoxyphenyl]phenol

PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H30ClN3O3
Molar mass492.02 g·mol−1
3D model (JSmol)

  • c4cnc1cc(Cl)ccc1c4Nc(cc2CN(CC)CC)cc(c2O)-c(cc3OC)ccc3CO

  • InChI=1S/C28H30ClN3O3/c1-4-32(5-2)16-20-12-22(31-25-10-11-30-26-14-21(29)8-9-23(25)26)15-24(28(20)34)18-6-7-19(17-33)27(13-18)35-3/h6-15,33-34H,4-5,16-17H2,1-3H3,(H,30,31)

  • Key:OFXBJOIYAJBMNY-UHFFFAOYSA-N

FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including hepatitis B, hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus. [1]

Mechanism[edit]

The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease.[2][3]

See also[edit]

References[edit]

  1. ^ Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. (January 2009). "FGI-104: a broad-spectrum small molecule inhibitor of viral infection". American Journal of Translational Research. 1 (1): 87–98. doi:10.1016/j.antiviral.2009.02.082. PMC 2776286. PMID 19966942.
  • ^ Janeba Z (November 2015). "Development of Small-Molecule Antivirals for Ebola". Medicinal Research Reviews. 35 (6): 1175–94. doi:10.1002/med.21355. PMC 7168439. PMID 26172225.
  • ^ Saxena A, Ferri M (2015). "Clinical Management of Ebola Virus Disease: Current and Future Approaches". In Saxena A (ed.). Communicable Diseases of the Developing World. Topics in Medicinal Chemistry. Vol. 29. Cham: Springer. pp. 1–36. doi:10.1007/7355_2015_5003. ISBN 978-3-319-78252-2.
    • Stub icon

    This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=FGI-104&oldid=1215443294"
    Categories: 
    ●Antiviral drugs
     ●Ebola
     ●Quinolines
     ●Chloroarenes
     ●Phenols
     ●Phenol ethers
     ●Diethylamino compounds
     ●Primary alcohols
     ●Antiinfective agent stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Chemical articles without CAS registry number
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without UNII source
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
     ●All stub articles
      


    ●This page was last edited on 25 March 2024, at 04:39 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki